Immune Disease patents
Bulk PDF Downloads
This page is updated frequently with new Immune Disease-related patent applications.
|Interferon regulatory factor 1 (irf1) decoys and methods of use thereof|
Compositions and methods for inhibiting, treating, and/or preventing autoimmune diseases such as lupus are provided.. .
The Children's Hospital Of Philadelphia
|Therapeutic antibodies and their uses|
The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to bcma (b-cell maturation antigen) and/or cd3 (cluster of differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the bcma antibodies, compositions comprising the bcma antibodies, and methods of using the bcma antibodies and their conjugates for treating conditions associated with cells expressing bcma (e.g., cancer or autoimmune disease).
|Compositions and methods to image and quantify inflammation|
Compositions and methods for assessing inflammation in a subject. The present disclosure provides compositions for labeling leukocytes with a 19f-containing perfluoropolyether molecule ex vivo.
|Ephedra alata extracts and methods of use thereof|
Ephedra alata aqueous extracts, powders and constituents thereof are encompassed herein, as are compositions thereof. Methods of using same for treating inflammatory diseases, autoimmune diseases, cancers, viral diseases, and neurodegenerative diseases are also envisioned..
|Tolerizing treatments for autoimmune disease|
The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory t-cells from the patient or a compatible donor, or (iii) a combination of regulatory t-cells and a compound identified by the methods described herein.
Enzo Biochem, Inc.
|Method for generating batches of allogeneic t-cells with averaged potency|
The present invention relates to a method for generating batches of lymphocytes with averaged potency. In particular, the present invention relates to a method of pooling lymphocytes from different donors to avoid nk alloreactivity and anti-hla immune response.
|Novel compound useful for the treatment of degenerative and inflammatory diseases|
A novel compound able to inhibit jak is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6.. .
|Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof|
The present invention relates to the compound according to formula i, and to its use in medicine, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons. In particular, the compound inhibits jak a family of tyrosine kinases, and more particularly jak1.
|Anti-cd20- / anti-baff bispecific antibodies|
Bispecific antibodies are provided that bind cd20 and b-cell activating factor of the tnf family (baff) and are characterized as having high affinity and strong simultaneous neutralizing properties to both cd20 and baff. The bispecific antibodies of the invention are useful for treating autoimmune diseases including systemic lupus erythematosus, lupus nephritis, and primary sjögren's syndrome..
Eli Lilly And Company
|Antibodies with altered binding to fcrn and methods of using same|
This invention relates to antibodies with altered binding to fcrn, and particularly antibodies having enhanced binding to fcrn and/or enhanced serum half-lives. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Il-17a binding agent and uses thereof
Provided is an antibody capable of specially recognizing il-17a and binding to il-17a. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17a, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis..
Jiangsu Hengrui Medicine Co., Ltd.
The present invention relates to novel compounds, e.g. For use as a medicament.
Agent and treating autoimmune disease
Provided is an agent for the treatment of an autoimmune disease, the agent comprising ctrp3, and a method for the treatment of an autoimmune disease, the method comprising: administering an agent, which comprises ctrp3 for the treatment of an autoimmune disease, to a subject in need of a treatment of an autoimmune disease.. .
Tokyo University Of Science Foundation
Immunoglobulin constant region fc receptor binding agents
Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function.
Diagnosis and treatment of autoimmune diseases
The invention relates generally to the field of autoimmunity. More specifically, the invention relates to compositions and methods for the diagnosis, prevention, and treatment of human leukocyte antigen (hla)-associated autoimmune diseases, and in particular hla-b27-associated autoimmune diseases..
Newsouth Innovations Pty Limited
Inhibitors of bruton's tyrosine kinase
This application discloses compounds according to generic formula i: wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.
N-terminal modified peg-trail
Disclosed herein are an n-terminal modified peg-trail conjugates and methods of making and using thereof. The peg-tail conjugates have bioactivity that is substantially similar to that of native trail coupled with an extended in vivo half-life and enhanced stability.
Theraly Pharmaceuticals Inc.
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
Disclosed are methods, compositions and uses of concentrated formulations of anti-cd74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (sle).
Provided herein are compositions (e.g., killer cell immunoglobulin-like receptor (kir)-targeting agents) that target a subset of t lymphocytes present in disease states (e.g., lupus and other autoimmune diseases) and methods of treating conditions and/or diseases therewith. In particular, anti-kir antibodies, fragments thereof, or related compositions are provided for the treatment of conditions and/or diseases (e.g., lupus and other autoimmune diseases, atherosclerosis, etc.)..
The Regents Of The University Of Michigan
Download all patent PDFs.
Bulk PDF Downloads25% Off COUPON CODE: mypdfs
Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
The novel positively charged pro-drugs of nsaias in the general formulas (1, 2a, 2b, 2c, or 2d) “structure 1, 2a, 2b, 2c, or 2d” were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) “structure 1, 2a, 2b, 2c, or 2d” indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of nsaias with suitable halide compounds.
Techfields Pharma Co., Ltd.
Compositions and methods for the prevention and treatment of autoimmune conditions
The methods include selectively reducing or expanding t cells according to the antigenic specificity of the t cells. Therefore, the present invention can be used to reduce or eliminate pathogenic t cells that recognize autoantigens, such as beta cell specific t cells.
Uti Limited Partnership
Methods of treating allergies and autoimmune diseases with homogenate of axenic c. elegans
Methods of using axenic c. Elegans homogenate for treating allergies or an autoimmune disease are disclosed.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
Modulators of syndecan-2 and uses thereof
Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndiecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a th17 mediated disease such as an autoimmune disease, fibrosis or cancer.. .
Orbsen Therapeutics Limited
Il-17 production inhibitory composition
Provided is a composition for preventing or treating il-17-related diseases, more specifically, autoimmune diseases and inflammatory diseases induced by an increase of il-17. The il-17 production inhibitory composition is characterized by containing mesenchymal stem cells originated from an adipose tissue as an active ingredient.
Anterogen Co., Ltd.
Polyethylene glycol-cactus oligopeptide bonding rapamycin derivatives
The present invention provides compounds represented by formula (i) and pharmaceutical acceptable salts thereof, preparation method therefor and pharmaceutical composition containing the compounds represented by formula (i) and pharmaceutical acceptable salts thereof. In the compounds of the present invention, each terminal group of polyethylene glycol molecule can bond with a plurality of rapamycin molecules by cactus oligopeptide, with the loading rate of the pharmaceutical being increased.
Jenkem Technology Co., Ltd.
Biological markers and methods for predicting response to b-cell antagonists
Biological markers that predict patient responsiveness to b-cell antagonists are provided. Also provided are methods of using such biological markers.
Methods of reducing serum levels of fc-containing agents using fcrn antagonists
Provided are novel methods of reducing the serum levels of fc-containing agents (e.g., antibodies and immunoadhesins) in a subject. These methods generally comprise administering to the subject an effective amount of an isolated fcrn-antagonist that binds specifically to fcrn with increased affinity and reduced ph dependence relative to the native fc region.
Il-3 blockade in systemic lupus erythematosus and multiple sclerosis
The present invention relates to anti-il-3 antibodies or il-3 binding fragments thereof for use in the treatment of an autoimmune disease selected from the group consisting of systemic lupus erythematosus and multiple sclerosis, and to pharmaceutical compositions comprising such an antibody or antibody fragment.. .
Novel scorpion toxin analogue and treating autoimmune diseases
A novel peptide analogue of the heterometrus spinnifer toxin hstx1 is disclosed along with its application as, for example, a therapeutic agent for treating an autoimmune disease such as multiple sclerosis (ms) or rheumatoid arthritis (ra). The analogue comprises a peptide with an amino acid substitution at amino acid position 14 of the wild-type (wt) peptide sequence (or a position corresponding to position 14 of the wt peptide sequence).
Baylor College Of Medicine
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.
Heteromaromatic compounds useful for the treatment of prolferative diseases
The present invention provides novel compounds of formula (i) and formula (ii), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.
Heteroaromatic compounds useful for the treatment of prolferative diseases
The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.
Immune Disease topics:
Type 1 Diabetes
Signs And Symptoms
Follow us on Twitter
This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.